Mitsubishi Tanabe Pharma America, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Phase 2
Completed
- Conditions
- Erythropoietic Protoporphyria (EPP)
- Interventions
- Drug: MT-7117 low doseDrug: PlaceboDrug: MT-7117 high dose
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03520036
- Locations
- 🇺🇸
University of Texas Medical Branch Porphyria Center, Galveston, Texas, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Mass Balance Study With MT-7117
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03503266
- Locations
- 🇬🇧
Investigational Centre, United Kingdom, United Kingdom
Definitive QT Study With MT-8554
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: MT-8554 Low doseDrug: MT-8554 High doseDrug: Placebo
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03471130
- Locations
- 🇬🇧
Investigational center, City Name, United Kingdom
Mass Balance Study With MT-8554
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: [14C] MT-8554
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03381404
- Locations
- 🇬🇧
Investigational center, City Name, United Kingdom
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Phase 2
Completed
- Conditions
- Menopause Hot Flashes
- Interventions
- Drug: MT-8554 5mgDrug: MT-8554 10mgDrug: PlaceboDrug: MT-8554 1mg
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 375
- Registration Number
- NCT03291067
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath